OJI  Vol.3 No.3 , September 2013
Inappropriateness of prostate cancer screening by PSA in young Algerian farmers
Abstract: Introduction: It is not yet established, in Algeria, a consensus on the use of prostate specific antigen (PSA) for the screening of prostate cancer (PCA) while some doctors speculate and recommend a serum-PSA assay to the young men. The objective is to assess the prevalence of PSA by age in young farmers. Methods: This study was undergone on 403 farmers, exposed to the risk of pesticides, aged between 30 - 70 years and living in rural areas of Saida (Western Algeria), during the period 2006 to 2012. The values of the PSA were collected during PCA screening and compared by statistical tests that revealed significant difference. Results: It was found that 15.6% of patients were under the age of 40 years. The total PSA (TPSA) increases with age and varies from 1 to 2 ng/ml for the respective age groups of 30 - 39 and 60 - 69 years. Approximately, 16.6% of men (or 1/6), who underwent PSA assay were under the age of 40 years. Conclusion: According to the recommendations of Algerian associations of cancer, men younger than 50 years may not be candidates for screening by PSA.
Cite this paper: Berroukche, A. , Bendahmane-Salmi, M. and Kandouci, B. (2013) Inappropriateness of prostate cancer screening by PSA in young Algerian farmers. Open Journal of Immunology, 3, 119-122. doi: 10.4236/oji.2013.33016.

[1]   Hamdi Cherif, M., Zaidi, Z., Abdellouche, D., et al. (2010) Registre du cancer de Sétif (Algérie): Incidence, tendance et survie, 1986-2005. Journal of African Cancer, 3-6.

[2]   Baldi, I. and Lebailly, P. (2007) Cancers et pesticides. Revue du praticien, 57, 40-44.

[3]   Blanchet, P. and Multigner, L. (2008) Pesticides et cancer de la prostate. Progrès en Urologie, 18, 19-21.

[4]   Tombal, B. (2006) Dosage de l’antigène spécifique prostatique: Quels sont les challenges en 2006? Cliniques Universitaires Saint Luc, Bruxelles.

[5]   Tombal, B. (2006) Over and underdiagnosis of prostate cancer. Urology Supplements, 5, 511-516. doi:10.1016/j.eursup.2006.02.019

[6]   Klotz, L. (2005) Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. European Urology, 47, 16-21. doi:10.1016/j.eururo.2004.09.010

[7]   Bernier, R. (1998) Dépistage du cancer de la prostate: Utilisation du PSA. Collège des médecins du Québec, 1-5.

[8]   Coley, C.M., Christopher, M., Barry, M.J., Fleming, C., Fahs, M.C. and Mulley, A.G. (1997) Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. Annals of Internal Medicine, 126, 468-479. doi:10.7326/0003-4819-126-6-199703150-00010

[9]   Conseil d’évaluation des technologies de la santé du Québec (1995) Le dépistage du cancer de la prostate: Evaluation des avantages, des effets indésirables et des couts. le conseil, Aout, Montréal.

[10]   Steinberg, G., Carter, B.S., Beaty, T.H., Childs, B. amd Walsh, P.C. (1990) Family history and the risk of prostate cancer. Prostate, 17, 337-347. doi:10.1002/pros.2990170409

[11]   Ravery, V. (2002) Les principes d’Utilisation du PSA et de ses dérivés dans la détection du cancer de la prostate. Points d’Actualité, 1, 17-19.

[12]   Safi, J.M. (2002) Association between chronic exposure to pesticides and recorded cases of human malignancy in Gaza Governorates (1990-1999). The Science of the Total Environment, 284, 75-84. doi:10.1016/S0048-9697(01)00868-3

[13]   Meyer, A., Chrisman, J., Costa Moreira, J. and Koifman, S. (2003) Cancer mortality among agricultural workers from Serrana Region, state of Rio de Janeiro, Brazil. Environmental Research, 93, 264-271. doi:10.1016/S0013-9351(03)00065-3

[14]   Bauvin, E., Remontet, L. and Grosclaude, P. (2003) Incidence and mortality of prostate cancer in France: Trends between 1978 and 2000. Progrès en Urologie, 13, 1334- 1339.

[15]   Carter, B.S., Beaty, T.H., Steinberg, G.D., Childs, B. and Walsh, P.C. (1992) Mendelian inheritance of familial prostate cancer. Mendelian inheritance of familial prostate cancer. National Academy of Sciences of USA, 89, 3367- 3371

[16]   Coulange, C. (2006) Du bon usage du PSA (Antigène spécifique prostatique): Recommandations de l’association Fran?aise d’urologie. E-mémoires de l’Académie Nationale de Chirurgie, 5, 19-21.